ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1661581
This article is part of the Research TopicNew horizons in stroke management: Volume IIView all articles
Cost-effectiveness of Edaravone Dexborneol Sublingual Tablet Versus Concentrated Solution for Injection for the Treatment of Acute Ischemic Stroke in China
Provisionally accepted
- 1China Pharmaceutical University, Nanjing, China
- 2State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Edaravone dexborneol sublingual tablet (EDSL) is a novel therapy for acute ischemic stroke (AIS), proven effective and safe. Its convenient dosage form also provides an alternative administration option, helping to enhance treatment accessibility. This study evaluates the cost-effectiveness of EDSL versus edaravone dexborneol concentrated solution for injection (EDCSI) from the Chinese healthcare system perspective. Methods: A combination of the short-term decision tree and long-term Markov model was constructed. Clinical data were derived from the TASTE-SL and TASTE trials. To adjust for baseline characteristics between the two treatment groups, stabilized inverse probability of treatment weighting (sIPTW) was applied, and both Average Treatment effect on the Treated (ATT) and Average Treatment Effect (ATE) weighted results were calculated to enhance comparability. Model parameters were extracted from published literature, public databases, and expert interviews. Sensitivity and scenario analyses were conducted to demonstrate the robustness of the base-case results. Results: There was no statistically significant difference in the proportion of patients achieving mRS score ≤1 between the EDSL and EDCSI groups after sIPTW (ATE: 69.3% vs. 64.6%; ATT: 71.8% vs. 67.6%). Notably, EDSL showed clear cost-effectiveness advantages, with an incremental cost-effectiveness ratio (ICER) of -¥2,089.84 per QALY gained. All sensitivity and scenario analyses confirmed the robustness of the base-case findings. Conclusion: EDSL represents a more cost-effective therapy for AIS patients compared to EDCSI, offering comparable efficacy at a lower drug cost. A full 14-day treatment course may help maximize patient benefits.
Keywords: Cost-Effectiveness, edaravone dexborneol, Sublingual tablets, acuteischemic stroke, China
Received: 09 Jul 2025; Accepted: 24 Sep 2025.
Copyright: © 2025 Xie, Lu, Yang, ZHANG, Bao and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yun Lu, luyuncpu@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.